BioSpace News Archive

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced the publication of a peer-reviewed meta-analysis and of an international Delphi consensus report based on a systematic, evidence-based review of endoscopic ultrasound (EUS) guided needle-based confocal laser endomicroscopy for pancreatic cystic lesion (PCL) evaluation. The

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that six abstracts have been accepted for presentation at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH), taking place virtually from December 5 to 8, 2020.

Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a first-in-class amyloid fibril targeted therapy, have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually from December 5 to 8, 2020

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that data from two of its clinical programs have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5 – 8, 2020

Avidea Technologies, Inc., a private biotechnology company developing immunotherapies through innovations in polymer-drug conjugate technologies, announced today the publication of preclinical studies in Nature Immunology showing how route of vaccine administration imprints on the quality of anticancer T cell responses that affect treatment efficacy.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced that two abstracts on the Company’s Antibody Radiation Conjugate (ARC) Iomab-B were accepted for oral presentations at the 2020 American Society of Hematology (ASH) annual meeting that is being held virtually December 5-8, 2020.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced that 100% of evaluable patients in the third and planned final dose cohort of the Actimab-A CLAG-M Phase 1 trial being conducted at the Medical College of Wisconsin (MCW) achieved remission.

ADDF recognizes Dr. Rook’s significant contributions toward advancing novel therapeutics that hold promise for treating Alzheimer’s and other central nervous system disorders

Orca Bio, a clinical-stage biotechnology company, today announced that preliminary data from the Phase I/II clinical trials of Orca-T (NCT04013685 and NCT01660607) will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting, to be held virtually from December 5-8, 2020.

Combination will be evaluated in patients with pancreatic ductal adenocarcinoma whose tumors have KRAS and CDKN2A mutations